Arestin - Use in Subjects With Peri-Implantitis (With Subgingival Microbiological Evaluation) - Full Text View

Purpose

The objective of the study is to evaluate the safety, effectiveness and anti-microbial effects of Arestin (minocycline HCl) 1 mg Microspheres in the treatment of subjects with peri-implantitis, when used in combination with mechanical debridement.

The hypothesis of the study is that Arestin in combination with mechanical debridement is more effective in the treatment of peri-implantitis when compared to mechanical debridement alone. The primary efficacy measure will be the reduction of probing depth at Day 180 as measured at qualifying implant sites.

Condition	Intervention	Phase
Peri-Implantitis	Drug: Minocycline HCl Microspheres	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Multi-Center Phase 3 Trial of Minocycline HCl 1 mg Microspheres for the Use in Subjects With Peri-Implantitis: Clinical and Microbiological Evaluations

Resource links provided by NLM:

Drug Information available for: Minocycline Minocycline hydrochloride

U.S. FDA Resources

Further study details as provided by OraPharma:

Primary Outcome Measures:

Change in mean Probing Depth of qualifying implant sites [ Time Frame: Baseline to Day 180 ]

Secondary Outcome Measures:

Change in percentage of qualifying implants with Bleeding On Probing [ Time Frame: Baseline to Day 180 ]
Change in mean Probing Depth of qualifying implant sites [ Time Frame: Baseline to Day 90 ]
Change in percentage of qualifying implants with Bleeding on Probing [ Time Frame: Baseline to Day 90 ]

Other Outcome Measures:

Exploratory: Changes in proportions and numbers of red-complex bacteria (RCB) [ Time Frame: Baseline to Day 30 ]


Enrollment:	208
Study Start Date:	May 2012
Study Completion Date:	November 2014
Primary Completion Date:	September 2014 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Treatment Treatment (minocycline HCl microspheres, 1mg) administered at Baseline (following randomization) and Day 90 to qualifying implant sites, plus full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180.	Drug: Minocycline HCl Microspheres Other Name: Arestin (brand name)
No Intervention: Control Full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180; no treatment

Eligibility


Ages Eligible for Study:	21 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

A minimum of one osseointegrated implant with a diagnosis of peri-implantitis
Absence of any significant oral soft tissue pathology
At least one peri-implant site with an average of 2 probing depth readings between 5mm and 7mm (inclusive) when using a light force and with bleeding on probing within 30 seconds of the probing
Confirmed evidence of pathologic bone loss
At least 1mm of keratinized gingiva present around the implant

Exclusion Criteria:

Pregnancy
Allergy to tetracycline-class drug(s)
Systemic medical condition(s) requiring antibiotic prophylaxis prior to invasive dental procedures
Presence of active systemic infectious disease such as hepatitis, HIV, history of tuberculosis
Diagnosis of clinically significant or unstable organic disease, or compromised healing potential
Signs of untreated advanced periodontal disease and/or poor oral hygiene
Subjects having a probing depth greater than 8mm at time of enrollment
Subjects presenting with mobility of any dental implant
Subjects having a qualifying implant under occlusal trauma or overloaded (as determined by the investigator)

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01517334

Locations


United States, Maryland
University of Maryland, School of Dentistry
Baltimore, Maryland, United States, 21201
United States, Massachusetts
Tufts University School of Dental Medicine
Boston, Massachusetts, United States, 02111
United States, Michigan
University of Michigan - Michigan Center for Oral Health Research
Ann Arbor, Michigan, United States, 48106
United States, Missouri
University of Missouri - Kansas City School of Dentistry Clinical Research Center
Kansas City, Missouri, United States, 64108
United States, North Carolina
University of North Carolina at Chapel Hill School of Dentistry
Chapel Hill, North Carolina, United States, 27599
United States, Pennsylvania
University of Pennsylvania School of Dental Medicine
Philadelphia, Pennsylvania, United States, 19104
United States, South Carolina
Medical University of South Carolina College of Dental Medicine
Charleston, South Carolina, United States, 29403
United States, Tennessee
UTHSC - College of Dentistry
Memphis, Tennessee, United States, 38163
United States, Virginia
Virginia Commonwealth University School of Dentistry
Richmond, Virginia, United States, 98056
United States, Wisconsin
Marquette University School of Dentstry
Milwaukee, Wisconsin, United States, 53233

Sponsors and Collaborators

OraPharma

Investigators


Principal Investigator:	Steven Offenbacher, DDS	University of North Carolina - Chapel Hill Dental School

More Information


Responsible Party:	OraPharma
ClinicalTrials.gov Identifier:	NCT01517334 History of Changes
Other Study ID Numbers:	OP-P-5266-M
Study First Received:	January 10, 2012
Last Updated:	August 25, 2015

Additional relevant MeSH terms:


Peri-Implantitis Periodontal Diseases Mouth Diseases Stomatognathic Diseases	Minocycline Anti-Bacterial Agents Anti-Infective Agents

ClinicalTrials.gov processed this record on May 25, 2017